Reporter brief
Metformin in Longevity Study (MILES).
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Whether metformin actually changed gene expression profiles or had any biological effect, as no results are presented.
- Whether any observed changes would be clinically meaningful or affect lifespan or age-related disease risk.
- Whether effects, if present, would extend to individuals without impaired glucose tolerance or diabetes.
Study design and sample
Rct; Human.
Older adults with impaired glucose tolerance (IGT), compared to young healthy subjects
- Design
- Rct
- Sample
- —
- Journal
- Albert Einstein College of Medicine
- Published
- May 21, 2021
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.